In his latest article for Pharmacy Times, Ned Milenkovich, chair of Much’s Health Care group, examined the prescription drug provisions in the One Big Beautiful Bill Act (OBBBA) and the ongoing debate over whether the legislation helps or harms patients. He discusses that while the legislation includes measures like expanded exemptions from Medicare, it could also weaken price-control efforts and threaten medication access for vulnerable populations.
Article
Examining the One Big Beautiful Bill Act on Prescription Drugs: Benefits and CriticismsPharmacy Times
8.5.2025
